Login to Your Account

DNA Beats Consensus With Avastin, Herceptin Growth

By Karen Pihl-Carey

Wednesday, October 12, 2005
Once again beating consensus estimates, Genentech Inc. reported a strong third quarter driven by better-than-expected sales of Avastin and Herceptin, two products that are increasingly being prescribed off-label. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription